Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1006129 | 0.85 | SMN1; SMN2 (0.36) | SMN1; SMN2PKMALDH1A1KDM4EPOLB | |
| SCHEMBL1005977 | 0.84 | CYP1A2 (0.33) | SMN1; SMN2PKMALDH1A1 | |
| SCHEMBL1007694 | 0.79 | ADORA2A (0.31) | CCNA2CDK2CCNA1 | |
| SCHEMBL1006750 | 0.77 | SMN1; SMN2 (0.32) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL1006877 | 0.76 | SMN1; SMN2 (0.32) | SMN1; SMN2 | |
| SCHEMBL6379773 | 0.69 | ALDH1A1 (0.36) | SMN1; SMN2PKMALDH1A1POLBTDP1 | |
| SCHEMBL18655534 | 0.68 | GABRA1 (0.32) | — | |
| SCHEMBL18632627 | 0.68 | ERCC1 (0.31) | — | |
| SCHEMBL18665244 | 0.68 | NPSR1 (0.35) | SMN1; SMN2ALDH1A1KDM4EPOLB | |
| SCHEMBL6383925 | 0.68 | ALDH1A1 (0.33) | SMN1; SMN2PKMALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-19 | — | — | US | disclosed |
| EP-2269990-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | GRIN1, GRM1, GRIK1 | SMN1; SMN2 3616/4885PKM 2797/4885ALDH1A1 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.